University of Cambridge Milner Logo


A tour of the new Institute last month, ready for the October opening.

Get connected with News@Milner

Welcome to the Milner Therapeutics Institute newsletter! The intention of this letter is to bring together the academic and industrial components of our Institute. Visit the Milner web site for further info »

Milner Update: May 2018

The Milner Team is growing!
Welcome to Namshik Han, who recently joined the Milner team as Computational Biology Programme Lead. Namshik will lead and develop an independent Computational Biology Group within the Milner Therapeutics Institute.

We are currently recruiting for a Global Alliance Manager, who will be responsible for developing and delivering an overarching strategy for the Alliance. For more details and to apply, please click here »

Did you know that we also have a team of Innovation Representatives? In partnership with Entrepreneurial Postdocs of Cambridge (EPOC) and the Innovation Forum, our Milner Innovation Representatives proactively reach out to other scientists in the department and facilitate interactions between academics and the Milner Institute.

Our call for representatives goes out once per year and we are pleased to announce that we are currently recruiting! For details and how to apply, please click here »

Two new affiliated companies, both using artificial intelligence in their technology, have also joined The Milner Institute this month. Welcome to OBRIZUM and Intellegens! Read more about each company in the spotlight section below.

Register Now: Milner Annual Symposium

This yearly networking event of 300+ scientists from biotech, pharma, CROs and academia is a fantastic opportunity to catalyse new partnerships and collaborations.

To see confirmed speakers and to register, please click here »

Save the Date: Charles River Roadshow

On 28th June 2018 we will co-host the Charles River Roadshow 2018 at Homerton College in Cambridge. This event is for both academics and industry scientists to present and discuss opportunities for innovation, collaboration and entrepreneurship in drug discovery.

To register your interest, please click here »

Affiliated Company Spotlight

Intellegens, a spin-out from the University of Cambridge, has developed a unique Artificial Intelligence (AI) method for training deep neural networks from incomplete data. The technique, developed at the Department of Physics, was originally established to design new superalloys for use in jet engines, however, the technique is generic and has now been applied in drug discovery, specifically looking at large compound / protein activity matrices.

Intellegens’ novel machine learning tool, AlcemiteTM, adds value to even the sparsest data, increasing the understanding from rare experimental results and reducing the number of future investigations required. Data sparseness has long been a stumbling block for applications of AI in computational drug discovery (the ChEMBL dataset, for example, is only 0.07% complete), but Intellegens’ tools can cope with the data sparseness and learn correlations between all the available data.

Intellegens’ AI models, trained on sparse data, can then be used to impute missing values in sparse chemical databases, correct errors and predict the activities of new molecules. AlchemiteTM can also be used to guide experiments to collect data that will maximize the accuracy of the model in a particular space.

This approach has been commercially proven with initial license agreements in place. Intellegens are now developing a suite of software tools to support the underlying algorithms and address a number of data analysis bottlenecks.

Intellegens are based in Cambridge and are interested in talking to partners who are facing sparse data / deep learning related problems.

For more information, visit the Intellegens website at here » or email Ben Pellegrini at

OBRIZUM® is an enterprise level cloud platform that allows companies in high-skill areas like healthcare, engineering, finance, law, and software, to automatically create, deliver and monitor adaptive online courses and assessments, on a global scale.

The hyper-modular courses are powered by deep proprietary Artificial Intelligence technology which personalises the presentation of content and assessments in real time based on the unique needs of the end-users. Using OBRIZUM®, managers can automatically create e-learning courses quickly and easily simply by 'dragging and dropping' content into the platform. Beyond formal e-learning, OBRIZUM’s AI technology makes complex or high volume content exchange between colleagues and departments faster and more efficient.

The personalised learning experience is user friendly and considerably faster than traditional linear e-learning. Tracking performance of individuals and teams using the platform’s analytics dashboards is easy and global data is updated instantaneously. The OBRIZUM® platform is poised to disrupt corporate education and transform the trading of knowledge both within and between organisations. The platform is built to overcome the content, cost, scale and efficiency challenges of providing learning and development programmes to a globally distributed workforce or student base.

For more information, visit the OBRIZUM website at here » or email Sarra Achouri at

Affiliated Company News

STORM Therapeutics wins Life Science Innovation Award at the Business Weekly Awards. Read more »

Agilent Technologies win the Daniel J. Epstein Engineering Management Award at 40th Viterbi Awards. Read more »

Linguamatics wins Megabuyte Best Performing Company award.Read more »

Sphere Fluidics is a finalist in Red Herring’s Top 100 European Start-Ups. Read more »

BTG and SIO Announce Recipients of Immuno-Oncology/Interventional Oncology Grant Program. Read more »

Eagle Genomics have been chosen as a 2018 Red Herring Top 100 Europe Winner. Read more »

Sanofi Adopts Genedata Selector to Optimize Strain Development. Read more »

Global investors engage in potential $10m Healx Series A. Read more »

Horizon Discovery enters into partnership with Pirbright Institute to support research into improvement of vaccine yields. Read more »

O2h discovery and Curza announce a multi-FTE chemistry collaboration against gram negative bacteria. Read more »

PhoreMost and NeoPhore receive Innovate UK funding to support development of a novel small-molecule cancer immunotherapy programme. Read more »

Selcia, Parkinson's UK and Cresset collaborate to discover new drug candidates for Parkinson's Disease. Read more»

Ubiquigent and Forma Therapeutics enter an exclusive R&D collaboration to develop novel DUB inhibitors. Read more »

BioAscent to attend the 2018 SLAS Europe Compound Management Conference in Berlin. Read more »

The application process is now open for the MedAnnex/University of Glasgow, four-year PhD , "Annexin-A1 as a target for T cell mediated pathology in psoriatic arthritis”. Read more »

Biomax Informatics AG announces a multi-year licence with Boehringer Ingelheim to support their global target discovery research. Read more »


Postdoc Business Plan Competition 2018: now open for entries!
2nd May - 6th July

Are you a Cambridge postdoc looking to move your business idea forward? If so, now's the time to start your entrepreneurial journey! Submit your business plan today to be in with a chance of winning funding for your idea of up to £20k, as well as mentoring and support. Read more »

BioWednesday Cambridge: Repurposing Drugs – Opportunities and Challenges
9th May, Cambridge

This BioWednesday will explore how drugs can be repurposed, with examples from those working in this area. It will also focus on challenges faced with obtaining patents for repurposed drugs and strategies to overcome these hurdles. Read more »

Postdoc Masterclass Seminar Series: Network Analysis of Large-Scale Human Neuroimaging Data
9th May, Cambridge

The aim of this series is to provide a forum for expert reviews and discussion on 'hot topics' and current techniques in Biology. The series is now organised by Postdocs in Biology throughout Cambridge and open to all researchers from the Departments of Biological Sciences. Read more »

Pitchfest 2018
Dates in May 2018, Cambridge

Pitchfest 2018 is a highly focused training and showcase programme designed to help ambitious business founders develop the necessary skills to become pitch ready.
Pitchfest culminates with a Showcase where 15 selected companies pitch their business ideas to investors with ample networking available to allow a deeper conversation about their ventures. Read more »

Cambridge Technologies Ventures Conference
20th June, Cambridge

CUTEC (Cambridge University Technology & Enterprise Club) has brought together a range of high profile speakers from big tech companies to biotech start-ups, to discuss the future of biotech in healthcare. Read more »

ON Helix
10th & 11th July, Cambridge

ON Helix is One Nucleus' annual translational research conference for the Life Sciences industry. The two-day event aims at informing delegates of how to turn early stage inventions and ideas into innovative health treatments (new medicines, novel biomarkers, useful medical devices or improved medical practices). Read more »

For more events please click here »


Production Manager: Life Sciences, Definigen. Read more »

Machine Learning AI Research Scientist , Intellegens. Read more »

Director of Chemistry, BioAscent. Read more »

Data Scientist: Data Insight, Cambridge Epigenetix. Read more »

Associate Scientist, Charles River Laboratories. Read more »

Business Development Manager, Genedata. Read more »

Principal Scientist: Pharmacologist, Healx. Read more »

Professional Services Manager, Linguamatics. Read more »

Drug Discovery Scientist, PhoreMost. Read more »

Senior Data Scientist, Quid. Read more »

BioPharma Business Development Manager, Repositive. Read more »

Head of Biology, Ubiquigent. Read more »

Contact us

The Milner Institute
University of Cambridge
Tennis Court Road
Cambridge CB2 1QN, UK
Tel: +44 (0)1223 767111 |

Subscribe | Unsubscribe